Skip to main content

Find Clinical Trials

Home
Conditions
Carcinoma, Medullary

Clinical trial condition

Carcinoma, Medullary

Explore clinical trials studying Carcinoma, Medullary. Study availability and eligibility vary by location and protocol.

103 public trials 12 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Medullary trial results

Not Yet Recruiting

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

NCT06121271

Conditions: Adenocarcinoma, Bronchial and Thymic Neuroendocrine Tumour, Carcinoma, +13 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

NCT06079723

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
Locations: Power Life Sciences San Francisco, California, United States

View Trial Details

Completed

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin

NCT02856347

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
Locations: CHU Haut-Lévêque Bordeaux, France

CHU Limoges Limoges, France

CHU Timone Marseille, France

ICM Montpellier Montpellier, France

View Trial Details

Completed

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

NCT01298323

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +15 more
Locations: Investigational Site Number : 301 St Leonards, New South Wales, Australia

Investigational Site Number 301 St Leonards, Australia

Investigational Site Number 401 Vienna, Austria

Investigational Site Number : 401 Vienna, Austria

View all 66 locations

View Trial Details

Completed

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

NCT01496313

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +20 more
Locations: Research Site Houston, Texas, United States

Investigational Site Number : 1903 Olomouc, Czechia

Research Site Olomouc, Czechia

Investigational Site Number : 1901 Prague, Czechia

View all 30 locations

View Trial Details

Completed

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

NCT00410761

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +17 more
Locations: Investigational Site Number 3 Little Rock, Arkansas, United States

University Arkansas Site Number : 3 Little Rock, Arkansas, United States

Investigational Site Number 8 San Francisco, California, United States

USCF / Mt Zion Medical Center Site Number : 8 San Francisco, California, United States

View all 127 locations

View Trial Details

Completed

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer

NCT05534594

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +20 more
Locations: University Medical Centre Groningen Groningen, Provincie Groningen, Netherlands

View Trial Details

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385

Conditions: Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more
Locations: Mayo Clinic Hospital Phoenix, Arizona, United States

UC Irvine Medical Center Orange, California, United States

University of Colorado Anschutz Medical Campus Aurora, Colorado, United States

Georgetown University Medical Center Washington D.C., District of Columbia, United States

View all 71 locations

View Trial Details

Completed

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

NCT00381641

Conditions: Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +37 more
Locations: University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States

Decatur Memorial Hospital Decatur, Illinois, United States

NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States

Ingalls Memorial Hospital Harvey, Illinois, United States

View all 17 locations

View Trial Details

Completed

Predictive Factors for Medullary Thyroid Cancer Aggressiveness

NCT06292988

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more
Locations: Oregon Health & Science University, Oregon Oregon City, Oregon, United States

Department of Surgery, Saint John of God Hospital, Salzburg, Austria Salzburg, Austria

Saint Luc, University Clouvain, Belgium Brussels, Belgium

Head and Neck Surgery Department, Hospital Ana Nery, Santa Cruz do Sul, Brazil Santa Cruz do Sul, Brazil

View all 46 locations

View Trial Details